Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older

NCT04636697 is registered in ClinicalTrials.gov with Medicago as lead sponsor.

NCT NCT04636697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04636697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older
Lead sponsor
Medicago
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
November 19, 2020
Completion date
April 30, 2022
Enrollment
30,918 (estimated)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection